Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the...

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...